Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
暂无分享,去创建一个
Zhihua Liu | Y. Zeng | Zong-tang Sun | Weilong Zhang | Y. Jiao | Hongwei Zheng | J. Cai | Hong Zhao | P. Ma | Zhi-yuan Wu | Xiaoyue Wang | C. Qu | Qifeng Wu | Siyuan He | Huan He | M. Zang | Ling-ling Lu | Nengjin Wang | Xiaoyan Chen | Ying Zhang
[1] Olfat Al-Harazi,et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells , 2015, Molecular Cancer.
[2] Niko Välimäki,et al. CTCF/cohesin-binding sites are frequently mutated in cancer , 2015, Nature Genetics.
[3] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[4] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[5] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[6] Peter J. Campbell,et al. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency , 2014, Genome research.
[7] R. Teschke. Traditional Chinese Medicine Induced Liver Injury , 2014, Journal of clinical and translational hepatology.
[8] R. Purcell,et al. The BAI subfamily of adhesion GPCRs: synaptic regulation and beyond. , 2014, Trends in pharmacological sciences.
[9] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[10] P. A. Futreal,et al. Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool , 2013, Science Translational Medicine.
[11] K. Kinzler,et al. Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing , 2013, Science Translational Medicine.
[12] S. Thorgeirsson,et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. , 2013, Carcinogenesis.
[13] Zhongming Zhao,et al. VirusFinder: Software for Efficient and Accurate Detection of Viruses and Their Integration Sites in Host Genomes through Next Generation Sequencing Data , 2013, PloS one.
[14] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[15] Niruthika Sritharan,et al. Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.
[16] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[17] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[18] William Stafford Noble,et al. Integrative annotation of chromatin elements from ENCODE data , 2012, Nucleic acids research.
[19] Felicia Wu,et al. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. , 2012, European journal of cancer.
[20] Bin Tean Teh,et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes , 2012, Nature Genetics.
[21] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[22] C. V. Jongeneel,et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.
[23] Erwin G. Van Meir,et al. Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development , 2011, Journal of Molecular Medicine.
[24] J. Groopman,et al. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[25] A. Jemal,et al. Global Cancer Statistics , 2011 .
[26] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[27] Yihai Cao,et al. Adipose angiogenesis: quantitative methods to study microvessel growth, regression and remodeling in vivo , 2010, Nature Protocols.
[28] Elias Campo Guerri,et al. International network of cancer genome projects , 2010, Nature.
[29] Yan Liu,et al. Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.
[30] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[31] Tom Royce,et al. A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.
[32] P. Chow,et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. , 2009, The Lancet. Oncology.
[33] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[34] Hyunsuk Shim,et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. , 2009, Cancer research.
[35] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .
[36] Timothy D Phillips,et al. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. , 2004, The American journal of clinical nutrition.
[37] S. Batalov,et al. A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Groopman,et al. Translational strategies for cancer prevention in liver , 2003, Nature Reviews Cancer.
[39] S. Thorgeirsson,et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China , 2002, Hepatology.
[40] L. Bulacio,et al. Aflatoxin B1 content in patients with hepatic diseases. , 2002, Medicina.
[41] Erwin G. Van Meir,et al. Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.
[42] Yusuke Nakamura,et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis , 1997, Oncogene.
[43] J. Wands,et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.
[44] R. A. Metcalf,et al. Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.
[45] R. Metcalf,et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.